{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:36:04Z","timestamp":1793108164388,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nationaal MS fonds","award":["P2021-001"],"award-info":[{"award-number":["P2021-001"]}]},{"name":"Stichting MOVES \u2018Klimmen tegen MS\u2019","award":["Inspiratiebeurs"],"award-info":[{"award-number":["Inspiratiebeurs"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17254-0","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:50:10Z","timestamp":1758883810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antinuclear antibodies in early multiple sclerosis reflect systemic lupus erythematosus shared risk factors"],"prefix":"10.1038","volume":"15","author":[{"given":"Cato E. A.","family":"Corsten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Masmanidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kamran","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin M.","family":"van Luijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrijs","family":"Wokke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"17254_CR1","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B. & Ciccarelli, O. Multiple sclerosis. Lancet 391, 1622\u20131636 (2018).","journal-title":"Lancet"},{"issue":"6578","key":"17254_CR2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science 375(6578), 296 (2022).","journal-title":"Science"},{"issue":"6460","key":"17254_CR3","doi-asserted-by":"publisher","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365(6460), eaav7188 (2019).","journal-title":"Science"},{"key":"17254_CR4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tig.2017.09.004","volume":"33","author":"SE Baranzini","year":"2017","unstructured":"Baranzini, S. E. & Oksenberg, J. R. The genetics of multiple sclerosis: From 0 to 200 in 50 years. Trends Genet. 33, 960\u2013970 (2017).","journal-title":"Trends Genet."},{"issue":"7359","key":"17254_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359), 214\u2013219 (2011).","journal-title":"Nature"},{"issue":"4","key":"17254_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1474-4422(14)70305-9","volume":"14","author":"B Hemmer","year":"2015","unstructured":"Hemmer, B., Kerschensteiner, M. & Korn, T. Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol. 14(4), 406\u2013419 (2015).","journal-title":"Lancet Neurol."},{"key":"17254_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104465","volume":"89","author":"L Bogers","year":"2023","unstructured":"Bogers, L. et al. Selective emergence of antibody-secreting cells in the multiple sclerosis brain. EBioMedicine 89, 104465 (2023).","journal-title":"EBioMedicine"},{"key":"17254_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2015.00636","volume":"6","author":"L Michel","year":"2015","unstructured":"Michel, L. et al. B cells in the multiple sclerosis central nervous system: Trafficking and contribution to CNS-compartmentalized inflammation. Front. Immunol. 6, 636 (2015).","journal-title":"Front. Immunol."},{"issue":"12","key":"17254_CR9","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.4103\/1673-5374.313045","volume":"16","author":"J den Dunnen","year":"2021","unstructured":"den Dunnen, J., Mes, L., Hoepel, W. & Smolders, J. Multiple sclerosis: Why we should focus on both sides of the (auto)antibody. Neural Regen. Res. 16(12), 2422\u20132424 (2021).","journal-title":"Neural Regen. Res."},{"issue":"28","key":"17254_CR10","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.1073\/pnas.1522730113","volume":"113","author":"SM Brandle","year":"2016","unstructured":"Brandle, S. M. et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc. Natl. Acad. Sci. U. S. A. 113(28), 7864\u20137869 (2016).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"17254_CR11","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41588-024-01732-8","volume":"56","author":"MR Lincoln","year":"2024","unstructured":"Lincoln, M. R. et al. Genetic mapping across autoimmune diseases reveals shared associations and mechanisms. Nat. Genet. 56(5), 838\u2013845 (2024).","journal-title":"Nat. Genet."},{"issue":"8","key":"17254_CR12","doi-asserted-by":"publisher","first-page":"e1002254","DOI":"10.1371\/journal.pgen.1002254","volume":"7","author":"C Cotsapas","year":"2011","unstructured":"Cotsapas, C. et al. Pervasive sharing of genetic effects in autoimmune disease. Plos Genet. 7(8), e1002254 (2011).","journal-title":"Plos Genet."},{"issue":"2","key":"17254_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/WNL.45.2.384","volume":"45","author":"S Barned","year":"1995","unstructured":"Barned, S., Goodman, A. D. & Mattson, D. H. Frequency of anti-nuclear antibodies in multiple sclerosis. Neurology 45(2), 384\u2013385 (1995).","journal-title":"Neurology"},{"issue":"3","key":"17254_CR14","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1212\/WNL.49.3.857","volume":"49","author":"RC Collard","year":"1997","unstructured":"Collard, R. C., Koehler, R. P. & Mattson, D. H. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 49(3), 857\u2013861 (1997).","journal-title":"Neurology"},{"issue":"4","key":"17254_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archneur.55.4.517","volume":"55","author":"A Tourbah","year":"1998","unstructured":"Tourbah, A. et al. Systemic autoimmune features and multiple sclerosis: A 5-year follow-up study. Arch. Neurol. 55(4), 517\u2013521 (1998).","journal-title":"Arch. Neurol."},{"issue":"2","key":"17254_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/135245859900500209","volume":"5","author":"M Spadaro","year":"1999","unstructured":"Spadaro, M. et al. Autoimmunity in multiple sclerosis: Study of a wide spectrum of autoantibodies. Mult. Scler. J. 5(2), 121\u2013125 (1999).","journal-title":"Mult. Scler. J."},{"issue":"4","key":"17254_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/0961203311427550","volume":"21","author":"M Szmyrka-Kaczmarek","year":"2012","unstructured":"Szmyrka-Kaczmarek, M. et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus 21(4), 412\u2013420 (2012).","journal-title":"Lupus"},{"issue":"1","key":"17254_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41983-021-00284-6","volume":"57","author":"H Alnajashi","year":"2021","unstructured":"Alnajashi, H. & Alshamrani, F. Prevalence of antinuclear antibody in patients with multiple sclerosis: A case-control study. Egypt. J. Neurol. Psych. 57(1), 27 (2021).","journal-title":"Egypt. J. Neurol. Psych."},{"issue":"8","key":"17254_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.neurol.2021.11.016","volume":"178","author":"S Mejdoub","year":"2022","unstructured":"Mejdoub, S. et al. Antinuclear antibodies positivity is not rare during multiple sclerosis and is associated with relapsing status and IgG oligoclonal bands positivity. Rev. Neurol. 178(8), 812\u2013816 (2022).","journal-title":"Rev. Neurol."},{"key":"17254_CR20","doi-asserted-by":"publisher","first-page":"105639","DOI":"10.1016\/j.msard.2024.105639","volume":"87","author":"J Koshorek","year":"2024","unstructured":"Koshorek, J. et al. Relevance of antinuclear antibody in diagnosis and characteristics of multiple sclerosis. Mult. Scler. Relat. Disord. 87, 105639 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"17254_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","volume":"16","author":"DS Pisetsky","year":"2020","unstructured":"Pisetsky, D. S. & Lipsky, P. E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 16(10), 565\u2013579 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"17254_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(11)70274-5","volume":"11","author":"DH Miller","year":"2012","unstructured":"Miller, D. H., Chard, D. T. & Ciccarelli, O. Clinically isolated syndromes. Lancet Neurol. 11(2), 157\u2013169 (2012).","journal-title":"Lancet Neurol."},{"issue":"9","key":"17254_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer, M. et al. 2019 European league against Rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 78(9), 1151\u20131159 (2019).","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"17254_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16(3), 1215 (1988).","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"17254_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/bioinformatics\/btu848","volume":"31","author":"J Euesden","year":"2015","unstructured":"Euesden, J., Lewis, C. M. & O\u2019Reilly, P. F. PRSice: Polygenic risk score software. Bioinformatics 31(9), 1466\u20131468 (2015).","journal-title":"Bioinformatics"},{"issue":"7","key":"17254_CR26","doi-asserted-by":"publisher","first-page":"giz082","DOI":"10.1093\/gigascience\/giz082","volume":"8","author":"SW Choi","year":"2019","unstructured":"Choi, S. W. & O\u2019Reilly, P. F. PRSice-2: Polygenic risk score software for biobank-scale data. Gigascience 8(7), giz082 (2019).","journal-title":"Gigascience"},{"issue":"12","key":"17254_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1474-4422(09)70275-3","volume":"8","author":"PL De Jager","year":"2009","unstructured":"De Jager, P. L. et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: A weighted genetic risk score. Lancet Neurol. 8(12), 1111\u20131119 (2009).","journal-title":"Lancet Neurol."},{"issue":"12","key":"17254_CR28","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/ng.3434","volume":"47","author":"J Bentham","year":"2015","unstructured":"Bentham, J. et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat. Genet. 47(12), 1457 (2015).","journal-title":"Nat. Genet."},{"issue":"1\u20132","key":"17254_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2009.05.004","volume":"406","author":"M Zivkovic","year":"2009","unstructured":"Zivkovic, M. et al. The tag SNP for HLA-DRB1*1501, rs3135388, is significantly associated with multiple sclerosis susceptibility: Cost-effective high-throughput detection by real-time PCR. Clin. Chim. Acta 406(1\u20132), 27\u201330 (2009).","journal-title":"Clin. Chim. Acta"},{"key":"17254_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"A Thompson","year":"2018","unstructured":"Thompson, A. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"issue":"3","key":"17254_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"CM Poser","year":"1983","unstructured":"Poser, C. M. et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 13(3), 227\u2013231 (1983).","journal-title":"Ann. Neurol."},{"key":"17254_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","volume":"122","author":"G Schumacher","year":"1965","unstructured":"Schumacher, G. et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. N. Y. Acad. Sci. 122, 552\u2013568 (1965).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"17254_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10238-018-0535-0","volume":"19","author":"ZX Li","year":"2019","unstructured":"Li, Z. X., Zeng, S., Wu, H. X. & Zhou, Y. The risk of systemic lupus erythematosus associated with Epstein\u2013Barr virus infection: A systematic review and meta-analysis. Clin. Exp. Med. 19(1), 23\u201336 (2019).","journal-title":"Clin. Exp. Med."},{"key":"17254_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.imlet.2023.07.006","volume":"261","author":"L Bogers","year":"2023","unstructured":"Bogers, L., Kuiper, K. L., Smolders, J., Rip, J. & van Luijn, M. M. Epstein\u2013Barr virus and genetic risk variants as determinants of T-bet+ B cell-driven autoimmune diseases. Immunol. Lett. 261, 66\u201374 (2023).","journal-title":"Immunol. Lett."},{"issue":"11","key":"17254_CR35","doi-asserted-by":"publisher","first-page":"e1003926","DOI":"10.1371\/journal.pgen.1003926","volume":"9","author":"NA Patsopoulos","year":"2013","unstructured":"Patsopoulos, N. A. et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. Plos Genet. 9(11), e1003926 (2013).","journal-title":"Plos Genet."},{"issue":"5","key":"17254_CR36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ajhg.2012.08.026","volume":"91","author":"DL Morris","year":"2012","unstructured":"Morris, D. L. et al. Unraveling multiple MHC gene associations with systemic lupus erythematosus: Model choice indicates a role for HLA alleles and non-HLA genes in Europeans. Am. J. Hum. Genet. 91(5), 778\u2013793 (2012).","journal-title":"Am. J. Hum. Genet."},{"issue":"8","key":"17254_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102871","volume":"20","author":"CP Mavragani","year":"2021","unstructured":"Mavragani, C. P. et al. Scleroderma specific autoantibodies and MS-like manifestations: A novel association?. Autoimmun. Rev. 20(8), 102871 (2021).","journal-title":"Autoimmun. Rev."},{"key":"17254_CR38","doi-asserted-by":"publisher","first-page":"101452","DOI":"10.1016\/j.msard.2019.101452","volume":"37","author":"P Wildner","year":"2020","unstructured":"Wildner, P., Stasiolek, M. & Matysiak, M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. Mult. Scler. Relat. Disord. 37, 101452 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"17254_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1212\/CON.0000000000001390","volume":"30","author":"CA Pardo","year":"2024","unstructured":"Pardo, C. A. Clinical approach to myelopathy diagnosis. Continuum (Minneap Minn). 30(1), 14\u201352 (2024).","journal-title":"Continuum (Minneap Minn)."},{"issue":"9","key":"17254_CR40","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1093\/rheumatology\/keaa902","volume":"60","author":"D Nikolopoulos","year":"2021","unstructured":"Nikolopoulos, D. et al. Demyelination with autoimmune features: A distinct clinical entity? Results from a longitudinal cohort. Rheumatology 60(9), 4166\u20134174 (2021).","journal-title":"Rheumatology"},{"issue":"10","key":"17254_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/ng.3395","volume":"47","author":"L Moutsianas","year":"2015","unstructured":"Moutsianas, L. et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47(10), 1107 (2015).","journal-title":"Nat. Genet."},{"key":"17254_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.898049","volume":"13","author":"DK Karathanasis","year":"2022","unstructured":"Karathanasis, D. K. et al. Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. Front. Pharmacol. 13, 898049 (2022).","journal-title":"Front. Pharmacol."},{"issue":"6","key":"17254_CR43","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1212\/01.wnl.0000237343.93389.35","volume":"67","author":"K Imrell","year":"2006","unstructured":"Imrell, K., Landtblom, A. M., Hillert, J. & Masterman, T. Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct. Neurology 67(6), 1062\u20131064 (2006).","journal-title":"Neurology"},{"issue":"Pt 6","key":"17254_CR44","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/aws105","volume":"135","author":"C Elliott","year":"2012","unstructured":"Elliott, C. et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 135(Pt 6), 1819\u20131833 (2012).","journal-title":"Brain"},{"issue":"35","key":"17254_CR45","doi-asserted-by":"publisher","first-page":"21512","DOI":"10.1073\/pnas.2011249117","volume":"117","author":"S Kuerten","year":"2020","unstructured":"Kuerten, S. et al. Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. Proc. Natl. Acad. Sci. U. S. A. 117(35), 21512\u201321518 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"17254_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1352458513494489","volume":"20","author":"E Sundqvist","year":"2014","unstructured":"Sundqvist, E. et al. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult. Scler. J. 20(2), 165\u2013173 (2014).","journal-title":"Mult. Scler. J."},{"issue":"19","key":"17254_CR47","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1212\/WNL.0000000000002099","volume":"85","author":"KL Munger","year":"2015","unstructured":"Munger, K. L. et al. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 85(19), 1694\u20131701 (2015).","journal-title":"Neurology"},{"issue":"7969","key":"17254_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","volume":"619","author":"The International Multiple Sclerosis Genetics Consortium","year":"2023","unstructured":"The International Multiple Sclerosis Genetics Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 619(7969), 323\u2013331 (2023).","journal-title":"Nature"},{"issue":"2","key":"17254_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0162-3109(84)90048-1","volume":"8","author":"RH Weisbart","year":"1984","unstructured":"Weisbart, R. H. & Colburn, K. Effect of corticosteroids on serum antinuclear antibodies in man. Immunopharmacology 8(2), 97\u2013101 (1984).","journal-title":"Immunopharmacology"},{"issue":"2","key":"17254_CR50","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/ar3271","volume":"13","author":"QZ Li","year":"2011","unstructured":"Li, Q. Z. et al. Risk factors for ANA positivity in healthy persons. Arthritis Res. Ther. 13(2), R38 (2011).","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"17254_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/RHU.0b013e3181bb971b","volume":"15","author":"GG Marin","year":"2009","unstructured":"Marin, G. G., Cardiel, M. H., Cornejo, H. & Viveros, M. E. Prevalence of antinuclear antibodies in 3 groups of healthy individuals. Jcr-J. Clin. Rheumatol. 15(7), 325\u2013329 (2009).","journal-title":"Jcr-J. Clin. Rheumatol."},{"issue":"11","key":"17254_CR52","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10067-008-0932-y","volume":"27","author":"U Wijeyesinghe","year":"2008","unstructured":"Wijeyesinghe, U. & Russell, A. S. Outcome of high titer antinuclear antibody positivity in individuals without connective tissue disease: A 10-year follow-up. Clin. Rheumatol. 27(11), 1399\u20131402 (2008).","journal-title":"Clin. Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17254-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17254-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:04:08Z","timestamp":1758884648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17254-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17254"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17254-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. van Luijn received research support from EMD Serono, Merck, Novartis, GSK and Idorsia Pharmaceutical Ltd. J. Smolders reports grants for scientific research from Biogen, Roche and Siemens Healthineers and received speaker and\/or consultancy fee of Biogen, Merck, Novartis, Roche and Sanofi. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32969"}}